Drug Profile

RAG 01

Alternative Names: RAG-01

Latest Information Update: 31 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ractigen Therapeutics
Class Antineoplastics; Immunotherapies; RNA
Mechanism of Action Tumour suppressor gene stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Bladder cancer

Most Recent Events

19 Mar 2026 NMPA approves IND application for RAG 01 in Bladder cancer
19 Mar 2026 Ractigen Therapeutics plans a phase II trial for Bladder cancer in China
22 May 2025 Updated efficacy, safety, adverse event and pharmacokinetic data from a phase I study in Bladder cancer presented at the 61^st Annual Meeting of the American Society of Clinical Oncology (ASCO 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com